What is the typical appearance of White Blood Cells (WBCs) in leukemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

White Blood Cell Appearance in Leukemia

In leukemia, WBCs typically appear as abnormal cells with specific morphologic features depending on the type: chronic lymphocytic leukemia shows small, mature lymphocytes with narrow cytoplasm and dense nuclei; chronic myeloid leukemia displays increased myeloid cells in all maturation stages with predominance of mature forms; and acute leukemias present with increased immature blast cells (≥20% blasts defining blast phase). 1

Chronic Lymphocytic Leukemia (CLL)

Morphologic Features

  • Small, mature-appearing lymphocytes with a narrow border of cytoplasm and dense nucleus lacking discernible nucleoli, with partially aggregated chromatin 1
  • Gumprecht nuclear shadows (smudge cells) found as cell debris are characteristic morphologic features 1
  • May be admixed with larger or atypical cells, cleaved cells, or prolymphocytes (up to 55% of blood lymphocytes) 1
  • Requires at least 5,000 clonal B lymphocytes/μL (5 × 10^9/L) in peripheral blood for diagnosis 1, 2

Immunophenotype

  • CLL cells coexpress CD5 (T-cell antigen) with B-cell markers CD19, CD20, and CD23 1
  • Characteristically low levels of surface immunoglobulin, CD20, and CD79b compared to normal B cells 1
  • Each clone restricted to either kappa or lambda light chain expression 1

Chronic Myeloid Leukemia (CML)

Bone Marrow and Blood Findings

  • Increased cellularity due to proliferation of myelopoiesis in all stages of maturation with predominance of mature forms 1
  • Basophilia is common, and eosinophils may be prominent 1
  • In chronic phase: <15% blasts in blood and bone marrow 1
  • Megakaryocytes are smaller than normal with hypolobulated nuclei 1

Peripheral Blood Characteristics

  • WBC count often exceeding 100 × 10^9/L 1
  • Presence of immature granulocytes (metamyelocytes, myelocytes, promyelocytes) with few or occasional myeloblasts 1
  • Peripheral blood absolute basophilia (≥200/mm³) is a distinguishing feature 3

Disease Progression Markers

  • Accelerated phase: 15-29% blasts (ELN criteria) or 10-19% blasts (WHO criteria) 1
  • Blast phase: ≥30% blasts (ELN criteria) or ≥20% blasts (WHO criteria) 1
  • Distinction between myeloid (70-80%) and lymphoid (20-30%) blast crisis requires immunocytology by flow cytometry 1

Acute Leukemias

Blast Cell Characteristics

  • At least 20% immature forms/blasts defines acute leukemia 1
  • Myeloid leukemia without maturation shows many immature forms/blasts with azurophilic granules 1
  • Myeloid leukemia with maturation displays heterogeneous differentiation with ring forms 1

Red Blood Cell Changes

Associated RBC Morphology

  • Acute myeloid leukemia (AML): presence of large central holes in RBCs 4
  • Acute lymphoblastic leukemia (ALL) and CML: thorn- and horn-like structures in RBCs 4
  • CLL: flaccid appearance of RBCs 4
  • These alterations represent pathophysiological signatures of anemia associated with leukemia 4

Clinical Pitfalls and Important Caveats

Diagnostic Considerations

  • Flow cytometry is essential to confirm clonality of circulating B lymphocytes in CLL 1
  • Distinguish CLL from other lymphoproliferative disorders: mantle cell lymphoma (CD5+/CD23-), B-cell prolymphocytic leukemia (high CD20/surface Ig, 50% lack CD5) 1
  • In CML, pre-leukemic phase may present with normal or mildly elevated WBC (3.6-14.3 K/mm³) but still shows BCR-ABL1 fusion 3

Treatment Decision Points

  • Elevated WBC count alone is NOT an indication for treatment in CLL 2
  • Treatment should be based on disease-related symptoms, progressive disease, or lymphocyte doubling time <6 months 2
  • Unlike acute leukemias, even markedly elevated WBC counts in CLL rarely cause leukostatic symptoms 2

Monitoring Parameters

  • Microvascular density in bone marrow (highlighted by CD34) shows tortuous vessels with abnormal branching in CML, distinguishing it from leukemoid reaction 3
  • Small, hypolobated megakaryocytes (highlighted by CD61) comprise 40% in pre-CML versus 13% in leukemoid reaction 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Chronic Lymphocytic Leukemia (CLL) and White Blood Cell Count

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Red cell morphology in leukemia, hypoplastic anemia and myelodysplastic syndrome.

Pathophysiology : the official journal of the International Society for Pathophysiology, 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.